NUVB News and Press, Nuvation Bio Inc. Class A

2026-06-26 01:38:39 ET More on Nuvation Bio Nuvation Bio: David Hung's Latest Venture Looks Undervalued At Current Level Nuvation Bio: Buy The Ibtrozi Launch (Rating Upgrade) Nuvation Bio Inc. (NUVB) Presents at Jefferies Global Healthcare Conference 2026 Transcript ...

Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes PR Newswire NEW YORK , June 25, 2026 Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment...

2026-06-25 09:36:18 ET So, since my March article "GSK Expanding Fast - Oncology, HIV, And Smart Acquisitions" , GSK's stock price tested the +3σ band formed from the VWAP, $58.80, but then corrected back to $51.10.... Read the full article on Seeking Alpha For furthe...

2026-06-25 07:12:39 ET More on Nuvation Bio Nuvation Bio: David Hung's Latest Venture Looks Undervalued At Current Level Nuvation Bio: Buy The Ibtrozi Launch (Rating Upgrade) Nuvation Bio Inc. (NUVB) Presents at Jefferies Global Healthcare Conference 2026 Transcript ...

Nuvation Bio Announces Proposed Convertible Senior Notes Offering PR Newswire NEW YORK , June 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announc...

2026-06-17 12:21:53 ET Clinical-stage biotech Nuvation Bio, focused on oncology therapeutics, reported a recent insider buy amid a year of sharp share price gains. On June 9, 2026, Director Robert Mashal reported the acquisition of 25,000 shares of Nuvation Bio (NYSE:NUVB) throu...

2026-06-15 10:38:58 ET I initiate coverage of Nuvation Bio ( NUVB ) with a moderate Buy rating. Following the June 2025 FDA approval of Ibtrozi (taletrectinib), Nuvation has transitioned into a commercial-stage oncology company bearing two value-driving assets.... Read...

2026-06-08 08:15:49 ET I've been growing fond of Nuvation Bio Inc. ( NUVB ). At first, I was bearish, but it has since become apparent that its lead drug, Ibtrozi, is becoming a popular and, dare I say, “preferred” option in ROS1+ non-small cell lung cancer (ROS1+ NSCLC).....

Nuvation Bio to Present at the Jefferies Global Healthcare Conference PR Newswire NEW YORK , May 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David ...

Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting PR Newswire   88% of TRUST-II patients reported improved or stable quality of life at first assessment, with ...